Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 6,856.0 | 6,357.0 | 6,091.0 | 6,691.0 | 6,877.0 | 6,869.0 | 6,702.0 | 6,156.0 |
| Revenue growth | 7.8% | 4.4% | -9.0% | -2.7% | 0.1% | 2.5% | 8.9% | -9.3% |
| Cost of goods sold | 5,643.0 | 5,266.0 | 5,119.0 | 5,483.0 | 5,594.0 | 5,536.0 | 5,392.0 | 5,046.0 |
| Gross profit | 1,213.0 | 1,091.0 | 972.0 | 1,208.0 | 1,283.0 | 1,333.0 | 1,310.0 | 1,110.0 |
| Gross margin | 17.7% | 17.2% | 16.0% | 18.1% | 18.7% | 19.4% | 19.5% | 18.0% |
| Selling, general and administrative | 496.0 | 433.0 | 403.0 | 439.0 | 483.0 | 484.0 | 503.0 | 476.0 |
| Research and development | 79.0 | 82.0 | 75.0 | 68.0 | 70.0 | 60.0 | 65.0 | 64.0 |
| EBITA | 998.0 | 491.0 | 551.0 | 205.0 | 640.0 | 733.0 | 821.0 | 615.0 |
| EBITA margin | 14.6% | 7.7% | 9.0% | 3.1% | 9.3% | 10.7% | 12.3% | 10.0% |
| Amortization of intangibles | 33.0 | 34.0 | 33.0 | 41.0 | | 41.0 | 39.0 | |
| EBIT | 965.0 | 457.0 | 518.0 | 164.0 | 640.0 | 692.0 | 782.0 | 615.0 |
| EBIT margin | 14.1% | 7.2% | 8.5% | 2.5% | 9.3% | 10.1% | 11.7% | 10.0% |
| Pre-tax income | 805.0 | 332.0 | 353.0 | -261.0 | 277.0 | 275.0 | 356.0 | 268.0 |
| Income taxes | 178.0 | 167.0 | 89.0 | 118.0 | 108.0 | 70.0 | 119.0 | 106.0 |
| Tax rate | 22.1% | 50.3% | 25.2% | | 39.0% | 25.5% | 33.4% | 39.6% |
| Earnings from continuing ops | 584.0 | 142.0 | 249.0 | -397.0 | 144.0 | 388.0 | 453.0 | 301.0 |
| Earnings from discontinued ops | | 7.0 | | -3.0 | 113.0 | -3.0 | -7.0 | -4.0 |
| Net income | 584.0 | 149.0 | 249.0 | -400.0 | 257.0 | 385.0 | 446.0 | 297.0 |
| Net margin | 8.5% | 2.3% | 4.1% | -6.0% | 3.7% | 5.6% | 6.7% | 4.8% |
| |
| Diluted EPS | $3.67 | $0.89 | $1.57 | ($2.56) | $0.89 | $2.36 | $2.78 | $1.86 |
| Shares outstanding (diluted) | 159.0 | 160.3 | 158.8 | 155.3 | 162.1 | 164.6 | 162.8 | 162.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|